CAR T-Cell Therapy
CAR T-cell therapy (also called CAR T) is a treatment for multiple myeloma that uses your immune system to attack myeloma cells.
What is CAR T-cell therapy?
CAR T-cell therapy is a type of multiple myeloma treatment that uses cells from the body's immune system to fight multiple myeloma. This is called immunotherapy.
The FDA has approved two CAR T-cell therapies:
- Abecma® (ide-cel)
- Carvykti® (cilta-cel)
Other CAR T-cell therapies for multiple myeloma are being studied in clinical trials.
How does CAR T-cell therapy work?
T cells are an important part of the body’s immune system, which protects the body from infection and disease. T cells are a type of white blood cell that attacks cancer cells. In patients with multiple myeloma, T cells do not attack myeloma cells like they should.
CAR T-cell therapy reprograms T cells to better target and destroy myeloma cells. In CAR T-cell therapy, your T cells are removed from your body and taken to a lab where they are genetically modified to recognize and fight myeloma cells. Then they are put back into your body in a process called an infusion.
How is CAR T-cell therapy given?
CAR T-cell therapy involves several steps over a few months:
Step 1: Collecting your T cells
First, your T cells are collected from a vein in your arm. This process is called leukapheresis (sometimes called apheresis).
Step 2: Changing your T cells into CAR T cells
Your T cells are sent to a lab, where they are made into CAR T cells. Scientists add proteins to the surface of your T cells, called CARs (chimeric antigen receptors). These genetically engineered T cells can find and attack proteins on the surface of multiple myeloma cells. Making CAR T cells takes about four weeks.
Step 3: Bridging therapy
While waiting for CAR T cells, you may need another treatment to keep your multiple myeloma from getting worse. Bridging therapy is given between the time your T cells are collected and when CAR T-cell therapy starts. Bridging therapy can include chemotherapy, radiation therapy, corticosteroids, or targeted therapies.
Step 4: Preparing you for CAR T cells
Before you are given CAR T-cell therapy, you will have low-dose chemotherapy for about five days to prepare your body for the CAR T cells. Low-dose chemotherapy will kill some – but not all – of your multiple myeloma cells. CAR T-cell therapy works best when there are still some multiple myeloma cells to attack. This process is called lymphodepletion, or conditioning treatment.
Step 5: Getting your CAR T cells
After your low-dose chemotherapy, CAR T cells are given at a hospital through an IV drip. This process takes 15 minutes to an hour.
Step 6: Monitoring for side effects
After getting CAR T-cell therapy, you will stay at the hospital for about a week to be monitored for side effects. For 4 weeks after receiving CAR T-cell therapy, you should plan to stay close (within 2 hours) to the hospital. During this time, your caregiver must stay with you 24-hours a day to watch for side effects.
How effective is CAR T-Cell therapy?
Clinical trials with CAR T-cell therapy showed promising response rates and progression-free survival rates that were greater than other standard of care treatments. Response rate means the percentage of people on therapy who responded to the therapy, and progression free survival means how long during and after treatment a patient goes on without their disease getting worse.
| Abecma (ide-cel) | Standard of Care Treatment | |
|---|---|---|
| Response Rate | 71% | 32% |
| Progression Free Survival | 14 months | 4 months |
In patients who had 2-4 prior treatments, 71% of patients on Abecma responded to treatment versus only 32% of patients who were on standard of care treatments. Additionally, patients on Abecma went 14 months without their disease worsening, compared to patients on standard therapies who went 4 months without their disease worsening. Standard of care therapies in this trial included:
- Darzalex® (daratumumab) + Pomalyst® (pomalidomide), and Dex (dexamethasone);
- Darzalex (daratumumab), Velcade® (bortezomib), and Dex (dexamethasone)
- Ninlaro® (ixazomib), Revlimid® (lenalidomide), and Dex (dexamethasone)
- Kyprolis® (carfilzomib) and Dex (dexamethasone)
- Empliciti® (Elotuzumab), Pomalyst (pomalidomide), and Dex (dexamethasone)
| Carvykti (cilta-cel) | Standard of Care Treatment | |
|---|---|---|
| Response Rate | 85% | 67% |
| Progression Free Survival | >30 months | 12 months |
In patients who had 1-3 prior treatments, 85% of patients on Carvykti responded to treatment versus only 67% of patients who were on standard of care treatments. Additionally, patients on Carvykti went more than 30 months without their disease worsening, compared to patients on standard therapies who went 12 months without their disease getting worse. Standard of care therapies in this trial included:
- Pomalyst (pomalidomide) + Velcade (bortezomib) + Dex (dexamethasone)
- Darzalex (daratumumab) + Pomalyst (pomalidomide) + Dex (dexamethasone)
Common side effects of CAR T-Cell Therapy
CAR T-Cell therapy can cause side effects, which vary from person to person and can range from mild to severe, though generally occur and resolve within 7-10 days following infusion of the T-cells.
Because side effects can be serious or life-threatening, your treatment team will carefully watch you for symptoms.
You will be monitored for signs of three common but serious side effects: cytokine release syndrome (CRS), neurotoxicity and infection.
Cytokine release syndrome (CRS)
CRS is a common and serious side effect of CAR T-cell therapy that happens when the immune system responds more aggressively than it should 9 out of 10 people who get CAR T-cell therapy will get CRS. Symptoms usually develop within 3-14 days after treatment. CRS usually begins with fever and flu-like symptoms. It can worsen quickly if not treated and become life-threatening or fatal, so it’s important to that you or your caregiver contact your treatment team immediately if you think you might have CRS. CRS symptoms include:
- Fever
- Chills
- Difficulty breathing
- Dizziness or lightheadedness
- Headache
- Confusion
- Fast heartbeat
Most symptoms of CRS can be managed with medication like Actemra (tocilizumab) and close monitoring.
Neurotoxicity
Neurotoxicity is a common and serious side effect of CAR T-cell therapy that involves any adverse effects to your nervous system. Neurotoxicity typically develops within 1 to 3 weeks of getting CAR T-cell therapy. It does not usually result in long-term side effects. Neurotoxicity symptoms include:
- Difficulty finding words or speaking
- Being confused, memory problems, or trouble concentrating
- Coordination problems (trouble walking, writing)
- Vision changes
- Headaches
- Personality changes
- Seizures
- Muscle weakness
Sometimes neurotoxicity requires quick treatment with supportive care, steroids, and antiseizure medications
Your treatment team and caregivers will watch you closely for signs of neurotoxicity. You or your caregiver should report symptoms of neurotoxicity to your treatment team as soon as you notice them.
Increased risk of infection
CAR T-cell therapy can weaken the immune system, which increases the risk of infections. This is especially true in the first few weeks after treatment. Most infections are caused by viruses or bacteria. To help prevent infections, your treatment team will prescribe medication to protect you against bacteria, fungi, and viruses for three to six months. If you develop an infection, you may receive a treatment called immunoglobulins (IVIG) to help fight it. There are also things you can do on your own to help prevent infections, like:
- Frequent handwashing and good hygiene practices
- Make sure foods are fully cooked
- Avoid large gatherings and crowded spaces, and people who are sick
- Stay hydrated
Rare Side-Effects of CAR T-cell Therapy
Parkinsonism
Less than 1% of patients who get CAR T experience Parkinsonism. Symptoms include moving slowly, stiff muscles, shaking, and trouble keeping balance and coordination. This can occur weeks to months after treatment. Treatment includes occupational and/or physical therapy, and drugs that destroy remaining CAR T cells, such as steroids or Cytoxan (a type of chemotherapy).
Secondary cancers
About 1 in every 10,000 people who get CAR T-cell therapy get a secondary cancer, usually within the first year after treatment. This is similar to the risk following other treatments. Symptoms depend on the type and location of the new cancer. Patients who get CAR T are regularly screened for other cancers.
Is CAR T-cell therapy an option for me?
Abecma is available to patients whose myeloma has returned after 2-4 prior therapies. Carvykti is available to patients whose myeloma has returned after 1-3 prior therapies. It’s important to learn about the benefits and side effects of CAR T-cell treatments. You will also need to consider practical things like travel, time away from home, and financial costs. For example, CAR T is only available at specialized centers so you and your caregiver may need to travel. You will need to stay close to your treatment center for at least 4 weeks after your infusion to be monitored for side effects. Your insurance may approve payment for CAR T-cell therapy, but some procedures or treatments may not be covered. If you need financial support, there are programs that can help.
- For Abecma, Bristol Myers Squibb offers a program called Cell Therapy 360 for patients who have health insurance through a private company or employer.
- For Carvykti, Johnson & Johnson offers the MyCARVYKTI® Patient Support Program, which assists with transportation, lodging, and out-of-pocket costs related to meals and other travel expenses during treatment.
- Blood Cancer United offers the Susan Lang Pre CAR T-cell Therapy Travel Assistance Program which can help with travel costs.
Reach out directly to these programs to learn more. Even if your treatment team may not recommend CAR T-cell therapy, it is still important to ask. Your treatment team will discuss with you if CAR T-cell therapy could be a good next step.
What is the role of the caregiver?
Before starting CAR T-cell therapy, you need to have a full-time caregiver to support you before, during, and after treatment.
Your caregiver must commit to be with you 24 hours a day, 7 days a week, for 4-8 weeks after your CAR T cell infusion.
Because caregivers play a major role throughout the CAR T cell process, it is important to choose someone who is responsible and trustworthy. Your caregiver will watch for any signs of fever, infection, and neurotoxicity symptoms (confusion, personality changes), and will contact your treatment team right away if they see any signs of these side effects.
The MMRF offers support groups for caregivers.
How will I feel after getting CAR T-cell therapy?
Recovering from CAR T-cell therapy can take several weeks or months. You will feel very tired, and you may not have much of an appetite. It is important to rest and take it easy. Returning to work or other regular activities may be physically and emotionally challenging. Talk to your treatment team about what you should expect.
Long term recovery
Your treatment team will help you prepare for long term recovery based on your treatment plan and how your multiple myeloma responds to CAR T-cell therapy. If you respond well to CAR T-cell therapy, you may not need any additional myeloma treatments to stay in remission. You will have follow-up appointments at one month, three months, and one year after the infusion to assess your progress and plan next steps.